CoreWeave Q1 Revenue Surges but Losses Widen; Waiting for Execution Proof Points

What happened

CoreWeave reported Q1 2026 revenue of $2.1B, more than doubling from a year ago, and a $99.4B backlog driven by AI demand, but the net loss widened to $740M and net interest expense hit $536M as capital spending surged. The company surpassed 1GW of active power and remains on track to exceed 1.7GW by year-end 2026, yet free cash flow was -$4.7B for the quarter, underscoring extreme capital intensity. The DeepValue report maintains a WAIT rating with a base case of $125, noting that the equity outcome hinges on converting backlog into recognized revenue through on-time capacity delivery and maintaining access to non-recourse financing near the current SOFR+2.25% benchmark. While Q1 results confirm robust demand and management's ability to scale, the widening losses and leverage leave no margin of safety at the current price of ~$114, making the stock a binary bet on execution and funding stability. Investors should stay on the sidelines until the next two quarters provide clearer evidence that active power additions are materially progressing toward the 1.7GW target and that incremental financing does not reprice higher.

Implication

CoreWeave's Q1 results are a mixed bag: strong revenue and backlog growth confirm AI demand, but rising losses and heavy debt ($11.2B net debt, 4.5x EBITDA) leave no safety margin. The stock's near-term path depends entirely on execution—specifically, whether active power scales to >1.7GW by YE2026 and whether new debt comes at terms similar to the recent DDTL 4.0 (SOFR+2.25%). Until these are demonstrated, the risk/reward is unfavorable; the DeepValue base case of $125 offers only ~10% upside, while the bear case of $70 implies ~39% downside. Position sizing should be minimal if any, with a re-assessment window of 3-6 months.

Thesis delta

Q1 2026 results affirm the demand narrative but do not alter the WAIT thesis. The widened net loss and persistent negative free cash flow reinforce the binary nature of the investment—success hinges on execution proofs, not just backlog growth. No change to the base case $125; attractive entry remains $95.